1-4 g PO TID
1 cup PO TID; 1-4 g powdered root/150 ml water
760-1520 mg DGL PO, AC, must mix w/saliva; 8-16 weeks
0.5-1 g PO powdered root qD-TID
Use no more than 4-6 weeks
Arthritis, bronchitis, dry cough, peptic ulcers, gastritis, infections (bacterial/viral), prostate cancer, sore throat, systemic lupus erythematosus, upper resp. inflammation
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
Lower extremity weakness
Breast cancer, cholestatic liver disorders, cirrhosis, CHF, diabetes mellitus, endometriosis, hormone sensitive conditions, hypertonia, hypersensitivity to licorice, hypertension, hypokalemia, ovarian cancer, renal insufficiency (severe), uterine cancer, uterine fibroids
Concurrent CYP 3A4 substrates or potassium-depleting agents
Impaired liver function
FDA consumer alert: Consuming >2 ounces/day for at least 2 weeks may cause hypokalemia and result in arrhythmia; adults aged 40 or older are at a higher risk (October 2011)
Pregnancy & Lactation
Pregnancy Category: unsafe
Lactation: avoid use
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Anti-inflammatory, expectorant; blocks PGE2 & PGF2-alpha metab.
DGL less effective for upper resp. symptoms